Stephenson, Joe

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 197

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 110

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 84

A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors

Jonker, D. J., Stephenson, J., Edenfield, W. J., Supko, J. G., Li, Y., Li, W., Hitron, M., Leggett, D., Kerstein, D., & Li, C. (2014) · Journal of Clinical Oncology

Cancer Cells and MetastasisMesenchymal stem cell research

Cited by 19

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Petrylak, D. P., Kantoff, P. W., Mega, A. E., Vogelzang, N. J., Stephenson, J., Fleming, M. T., Stambler, N., Petrini, M., Huang, K., & Israel, R. J. (2013) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 19

A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors

Laurie, S. A., Jonker, D. J., Edenfield, W. J., Stephenson, J., Keller, D., Hitron, M., Li, W., Li, Y., Gada, K., Gao, Y., et al. (2014) · Journal of Clinical Oncology

Cancer Cells and MetastasisCancer Mechanisms and Therapy

Cited by 14